Trevi Therapeutics Inc., which is developing a drug to treat chronic itching in patients with the skin condition prurigo nodularis, announced Tuesday it had completed enrollment in its latest drug trial.
The New Haven-based biopharmaceutical company, founded in 2011, is developing an investigational therapy called Haduvio.
Trevi indicated it has completed enrollment for its Phase 2b/3 trial, and the company anticipates reporting results in the second quarter of this year. Approximately 360 subjects are enrolled in the trial.
President and CEO Jennifer Good called it an “important milestone” in the development of Haduvio.
The drug is taken orally and provides an extended-release formulation of nalbuphine, which is currently approved in the U.S. and Europe and marketed as an injectable for pain.
“By targeting the pruritus associated with prurigo nodularis, Haduvio is designed to break the itch-scratch cycle which has a significant impact on patients’ quality of life,” Good said, in an announcement. “We look forward to seeing these results and advancing the development of Haduvio to address the unmet need of patients with pruritus across conditions.”
During the random, double-blind, placebo-controlled study, researchers will evaluate Haduvio’s safety and effectiveness for treating patients with the condition.
Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
